WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2018021762) NOVEL COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.:    WO/2018/021762    International Application No.:    PCT/KR2017/007853
Publication Date: 01.02.2018 International Filing Date: 20.07.2017
IPC:
C07D 209/22 (2006.01), C07D 209/42 (2006.01), A61K 31/404 (2006.01)
Applicants: HYUNDAI PHARM CO., LTD. [KR/KR]; 55, Jandari-gil, Pungse-myeon, Dongnamgu, Cheonan-si, Chungcheongnam-do 31213 (KR)
Inventors: LEE, In Hee; (KR).
KIM, Se Hoan; (KR).
MOON, Soon Young; (KR).
JANG, Jung In; (KR).
KANG, Seung Tae; (KR).
YOON, Hyun Ho; (KR).
LEE, Hyuck Ju; (KR).
RHEE, Jae Keol; (KR)
Agent: BAE, KIM & LEE IP GROUP; 11th Floor, 343, Gangnam-daero, Seocho-gu, Seoul 06626 (KR)
Priority Data:
10-2016-0094855 26.07.2016 KR
Title (EN) NOVEL COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
(FR) NOUVEAU COMPOSÉ, SON PROCÉDÉ DE PRÉPARATION, ET COMPOSITION PHARMACEUTIQUE LE CONTENANT
(KO) 신규 화합물, 이의 제조방법 및 이를 포함하는 약학 조성물
Abstract: front page image
(EN)The present invention relates to a novel compound inhibiting CDK5-mediated PPARγ phosphorylation, a preparation method therefor, and a pharmaceutical composition containing the same. The novel compound of the present invention binds to PPARγ with high affinity but does not induce transcriptional activity so as not to act as an agonist, does not cause side effects of a conventional anti-diabetic by blocking the phosphorylation activity of CDK5, and has improved pharmacological properties. Therefore, a pharmaceutical composition containing the compound of the present invention as an active ingredient can be usable in the treatment of metabolic diseases associated with PPARγ.
(FR)La présente invention concerne un nouveau composé inhibant la phosphorylation de PPARγ médiée par CDK5, son procédé de préparation et une composition pharmaceutique le contenant. Le nouveau composé de la présente invention se lie à PPARγ avec une affinité élevée mais n'induit pas d'activité transcriptionnelle de manière à ne pas agir comme un agoniste, ne provoque pas d'effets secondaires d'un anti-diabétique classique en bloquant l'activité de phosphorylation de CDK5, et a des propriétés pharmacologiques améliorées. Par conséquent, une composition pharmaceutique contenant le composé de la présente invention en tant qu'ingrédient actif peut être utilisée dans le traitement de maladies métaboliques associées à PPARγ.
(KO)본 발명은 CDK5에 의한 PPARγ 인산화를 억제하는 신규 화합물, 이의 제조방법 및 이를 포함하는 약학 조성물에 관한 것으로, 본 발명의 신규 화합물은 PPARγ에 고친화도로 결합하지만 유전자 전사(transcriptional activity)를 유도하지 않아 작용제(agonist)로 작용하지 않고, CDK5의 인산화 작용을 차단하여 종래의 당뇨병 치료제의 부작용이 발생하지 않을 뿐만 아니라, 약리물성이 우수하다. 따라서 본 발명의 화합물을 유효성분으로 포함하는 약학 조성물은 PPARγ 관련 대사성 질환을 치료하는데 유용하게 사용될 수 있다.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: Korean (KO)
Filing Language: Korean (KO)